Developing antibodies to fight insect-borne viruses
Project 5: mAb Development Flaviviruses and Alphaviruses
This study is working on developing new treatments using special antibodies to help people who are suffering from serious illnesses caused by viruses like dengue and chikungunya, with the hope of offering better protection and options for recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10863006 on NIH RePORTER |
What this research studies
This research focuses on creating and validating human monoclonal antibodies (mAbs) to combat severe diseases caused by flaviviruses and alphaviruses, such as dengue and chikungunya. The project employs various antibody discovery techniques to identify the most effective mAbs and explores how to combine them for enhanced protection against these viruses. Additionally, it aims to develop computational methods to improve the effectiveness of these antibodies and create treatments that mimic vaccine responses. The ultimate goal is to provide new therapeutic options for patients suffering from these viral infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been infected with or are at risk of infection from flaviviruses or alphaviruses.
Not a fit: Patients who are not affected by flavivirus or alphavirus infections are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antibody-based treatments that significantly reduce the severity of diseases caused by flaviviruses and alphaviruses.
How similar studies have performed: Previous research has shown promise in developing antibody treatments for similar viral infections, indicating a potential for success in this approach.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Crowe, James E — Washington University
- Study coordinator: Crowe, James E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.